Medicus Pharma Ltd. Common Stock

Day range

$2.41 – $2.63

Open

$2.53

Prev close

$2.50

Volume

23.98K

Market cap

$3.59M

Shares out

1.43M

• Delisting determinationOct 23, 2026

  On October 20, 2026, the Company received a delisting determination letter from Nasdaq indicating that the Company had not regained compliance with the Minimum Bid Price Requirement and that Nasdaq had determined to delist the Company's common shares and warrants from The Nasdaq Capital Market.

• Charter amendmentOct 16, 2026

  Medicus Pharma Ltd. (the "Company") effected a 1-for-50 share consolidation (the "Share Consolidation") of the Company's issued and outstanding common shares, no par value (the "Common Shares") by filing Articles of Amendment (the "Articles of Amendment") with the Ontario Ministry of Public and Business Service Delivery on October 12, 2026. The Share Consolidation and Articles of Amendment became effective on October 12, 2026 and the Common Shares began trading on a post-Share Consolidation basis on The Nasdaq Capital Market on October 12, 2026.

• Stock splitOct 7, 2026

  Medicus Pharma Ltd. (the "Company") today announced that it will effect a fifty-to-one consolidation (the "Share Consolidation") of the Company's common shares, no par value (the "Common Shares"), to be effective on October 12, 2026. As a result of the Share Consolidation, every 50 Common Shares issued and outstanding will be automatically exchanged for one new Common Share.

• Deal terminationSep 14, 2026

  On September 11, 2026, Medicus Pharma Ltd. and YA II PN, LTD. mutually agreed to terminate the Standby Equity Purchase Agreement, dated as of February 10, 2025, effective as of such date.

• Equity compensation grantSep 11, 2026

  On September 4, 2026, Medicus Pharma Ltd. (the "Company") awarded cash bonuses in the aggregate amount of approximately $1.45 million to certain officers and employees of the Company. Each of the recipients elected to forgo payment of his or her cash bonus and instead receive the value of such bonus in restricted common shares of the Company.

Days to cover

1.0

Short interest

3.69M

Avg volume

3.92M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
  positiveGlobeNewswire Inc.· Jul 31, 2026
• Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
  positiveGlobeNewswire Inc.· Nov 24, 2025
• Cartoning Machines Market Size to Approach USD 13.58 Bn by 2034
  positiveGlobeNewswire Inc.· Dec 24, 2024
• Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
  positiveGlobeNewswire Inc.· Dec 12, 2024